Page last updated: 2024-08-24

aripiprazole and Hyperprolactinaemia

aripiprazole has been researched along with Hyperprolactinaemia in 82 studies

Research

Studies (82)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's22 (26.83)29.6817
2010's45 (54.88)24.3611
2020's15 (18.29)2.80

Authors

AuthorsStudies
Coolen, HK; Glennon, JC; Kruse, CG; Lange, JH; Reinders, JH; Tolboom, JT1
Chen, J; Chen, Y; Gao, L; Hao, C; Jin, J; Liu, BF; Liu, X; Ma, R; Wu, Q; Zhang, G; Zheng, L1
Kim, SG; Seo, EH; Yang, HJ; Yoon, HJ1
Chen, Y; Feng, X; Guo, L; Kang, Z; Liao, Y; Lu, Z; Sun, Y; Yue, W; Zhang, Y1
Cai, J; Gao, M; Huang, J; Huang, Y; Kang, D; Li, L; Liu, F; Long, Y; Ou, J; Peng, X; Shao, P; Shao, T; Shen, Y; Song, C; Su, Y; Sun, M; Wang, W; Wang, X; Wu, Q; Wu, R; Xiao, J; Xie, P; Yang, Y1
Carlson, HE; Correll, CU; Kazimi, MM; Koch, MT1
Geracioti, TD; Strawn, JR1
Feng, X; Kang, Z; Liao, Y; Lu, T; Lu, Z; Sun, Y; Wang, L; Yan, H; Yue, W; Zhang, D; Zhang, Y1
Brand, BA; Hamers, IMH; Sommer, IE; Willemse, EJM1
Shad, MU; Yeager, A1
Abad-Santos, F; Koller, D1
Crespo-Facorro, B; García-Rizo, C; González-Rodríguez, A; Labad, J; Monreal, JA; Montalvo, I; Palao, D1
Besag, FMC; Salim, I; Vasey, MJ1
Alabbasi, AY; Nelson, LA; Rusgis, MM1
Bidollari, I; Claxton, A; Du, Y; Kelly, DL1
Shimoda, K; Shinozaki, M; Sugawara, N; Tasaki, M; Yasui-Furukori, N; Yokoyama, S1
Gunes, S1
Hall, W; Maneta, E; Mazher, OA1
Fryefield, K; Shad, MU1
Andreescu, N; Grădinaru, R; Nussbaum, L; Puiu, M; Suciu, L1
Liu, QS; Luo, T; Wei, B; Yang, YJ1
Medvedovici, A; Rădulescu, FŞ; Ranetti, AE; Voicu, V1
Bonete Llácer, JM; García Escudero, MA; Martínez Pastor, CJ; Ziadi Trives, M1
Li, X; Tang, Y; Wang, C1
Buchanan, RW; Dickerson, FB; Earl, AK; Feldman, S; Fischer, BA; Keller, WR; Kelly, DL; McMahon, RP; Shim, JC; Sullivan, KM; Warfel, D; Wehring, HJ1
Cavuto, M; De Berardis, D; Di Giannantonio, M; Fornaro, M; Girinelli, G; Iasevoli, F; Marini, S; Martinotti, G; Mazza, M; Perna, G; Piersanti, M; Serroni, N; Valchera, A1
Lozano, R; Marin, R; Santacruz, MJ1
Gu, N; Kane, JM; Li, H; Luo, J; Wang, C; Wang, X; Xie, S; Xu, X; Yu, W1
Glenmullen, J; Mattison, DR; Moore, TJ1
Bjelobaba, I; Budimirovic, DB; Kucka, M; Stojilkovic, SS; Tomić, M1
Bian, QT; Chen, JX; Correll, C; Liu, YH; Soares, JC; Su, YA; Wang, SL; Wei, LH; Yang, FD; Zhang, RZ; Zhang, XY1
Hu, LY; Hung, MB; Hung, YY; Lee, YT; Lu, T1
Ai, X; Ding, M; Ding, S; Gu, X; Huang, G; Li, X; Lv, L; Pang, L; Song, X; Zhao, J1
Baglivo, V; Balestrieri, M; Brambilla, P; Gregoraci, G; Isola, M; Meduri, M1
Culhane, C; Hope, J; Keks, NA1
Guo, Q; Li, C; Ouyang, Q; Qiao, Y; Shen, W; Sheng, J; Wen, H; Yang, F; Zhu, S1
Baymeeva, NV; Burminskiy, DS; Miroshnichenko, II; Morozova, MA; Platova, AI; Potanin, SS1
Badran, IA; Correll, CU; Curran, RL; DelBello, MP; Pedapati, EV; Peppers, V1
Hara, H; Kawashima, T; Kunitake, Y; Maruo, J; Minami, C; Mizoguchi, Y; Monji, A; Shimomura, Y; Sogawa, R1
Alphs, L; Correll, CU; Kim, E; Mao, L; Starr, HL1
An, FR; Chiu, HF; Jin, X; Li, L; Lok, GK; Ng, CH; Ungvari, GS; Wang, ZM; Wu, PP; Xiang, YT; Yang, R1
Aleksic, B; Banno, M; Fujioi, J; Iwamoto, K; Kikuchi, T; Ozaki, N1
Arango, C; Bernardo, M; Carrasco, JL; Crespo-Facorro, B; Cruz, JJ; Del Pino-Montes, J; García-Escudero, MA; García-Rizo, C; González-Pinto, A; Hernández, AI; Martín-Carrasco, M; Mayoral-Cleries, F; Mayoral-van Son, J; Montejo, ÁL; Mories, MT; Pachiarotti, I; Pérez, J; Ros, S; Vieta, E1
Abe, H; Funahashi, H; Ishida, Y; Naono, H; Naono-Nagatomo, K; Takeda, R; Uchimura, D1
Chen, CH; Lu, ML; Shen, WW1
Katsigiannopoulos, K; Kouvelas, D; Papazisis, G; Saitis, M1
Baker, RA; Byerly, MJ; Eudicone, JM; Marcus, RN; Tran, QV; Whitehead, R1
Bian, QT; Chen, JX; Haile, C; Kosten, TR; Liu, YH; Su, YA; Wang, N; Wang, SL; Yang, FD; Zhang, XY1
Capote, HA; Gengo, FM; Rainka, MM; Ross, CA1
Chen, ST; Hsiao, YL1
Albayrak, Y; Caykoylu, A; Ekinci, O; Kuloglu, M1
Deng, C; Huang, XF; Lian, J; Pai, N1
Manoj, P; Skopek, M1
Bae, KY; Kim, JM; Kim, SW; Shin, IS; Yang, SJ; Yoon, JS1
Hara, C; Ramos, MG; Rocha, FL1
Ishitobi, M; Kosaka, H; Murata, T; Shukunami, K; Wada, Y2
Chen, CK; Hsiao, CC; Huang, YS; Ree, SC1
Fujii, A; Furukori, H; Kaneko, S; Sugawara, N; Yasui-Furukori, N1
Lee, J; Ng, KW; Swapna, V1
Arends, J; Cohen, D; van Kooten, M1
Carlsson, A; Carlsson, ML; Johansson, AM; Rung, E; Rung, JP; Svensson, K1
Chou, J; Chung, MT; Lin, CH; Ma, H1
Chatziioannou, S; Filippopoulou, A; Lykouras, L; Peppa, M; Rizos, E; Tsigkaropoulou, E; Xelioti, I; Zompola, C1
Anandarajan, T; Bastiampillai, T; Dhillon, R; Tibrewal, P1
Mari, Jde J; Moreira, HC; Nunes, LV; Nunes, SO; Razzouk, D1
Ali, MW; Carson, WH; Ingenito, GG; Kane, JM; McQuade, RD; Saha, AR; Zimbroff, DL1
Anghelescu, I; Wolf, J1
Citrome, L; Volavka, J1
Ostroff, R; Wahl, R1
Kim, YK; Lee, BH; Park, SH1
Doraiswamy, PM; Levine, JG; Szarfman, A; Tonning, JM1
Gründer, G; Paulzen, M1
Chen, CK; Lin, SK1
Fiedler, U; Wolf, J1
Kessler, RM1
Conley, RR; Jung, DU; Kelly, DL; Liu, KH; Seo, YS; Shim, JC; Shin, JG; Shon, JH1
Lorenz, RA; Weinstein, B1
Perlis, RH1
Chen, CH; Huang, MC; Lu, ML1
Aitchison, KJ; McAllister, V; Mir, A; O'Keane, V; Shivakumar, K; Williamson, RJ1
Hazra, M; Mamo, DC; Remington, G1

Reviews

12 review(s) available for aripiprazole and Hyperprolactinaemia

ArticleYear
Pharmacological treatment strategies for antipsychotic-induced hyperprolactinemia: a systematic review and network meta-analysis.
    Translational psychiatry, 2022, 07-05, Volume: 12, Issue:1

    Topics: Antipsychotic Agents; Aripiprazole; Humans; Hyperprolactinemia; Network Meta-Analysis; Prolactin; Vitamin B 6

2022
Evidence-Based Recommendations for the Pharmacological Treatment of Women with Schizophrenia Spectrum Disorders.
    Current psychiatry reports, 2023, Volume: 25, Issue:11

    Topics: Aged; Antipsychotic Agents; Aripiprazole; Estrogens; Female; Humans; Hyperprolactinemia; Male; Raloxifene Hydrochloride; Schizophrenia

2023
Pharmacological treatment strategies for lowering prolactin in people with a psychotic disorder and hyperprolactinaemia: A systematic review and meta-analysis.
    Schizophrenia research, 2020, Volume: 222

    Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Humans; Hyperprolactinemia; Prolactin; Psychotic Disorders

2020
Is Adjunct Aripiprazole Effective in Treating Hyperprolactinemia Induced by Psychotropic Medication? A Narrative Review.
    CNS drugs, 2021, Volume: 35, Issue:5

    Topics: Antipsychotic Agents; Aripiprazole; Humans; Hyperprolactinemia; Prolactin; Psychotropic Drugs; Randomized Controlled Trials as Topic

2021
Drug-induced hypo- and hyperprolactinemia: mechanisms, clinical and therapeutic consequences.
    Expert opinion on drug metabolism & toxicology, 2013, Volume: 9, Issue:8

    Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Blood-Brain Barrier; Humans; Hyperprolactinemia; Isoxazoles; Paliperidone Palmitate; Piperazines; Prolactin; Pyrimidines; Quinolones; Receptors, Dopamine D2; Risperidone; Stress, Psychological; Sulpiride; Xenobiotics

2013
Adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia: meta-analysis of randomized controlled trials.
    PloS one, 2013, Volume: 8, Issue:8

    Topics: Antipsychotic Agents; Aripiprazole; Humans; Hyperprolactinemia; Piperazines; Placebos; Quinolones; Randomized Controlled Trials as Topic; Treatment Outcome

2013
Treatment of antipsychotic-induced hyperprolactinemia: an update on the role of the dopaminergic receptors D2 partial agonist aripiprazole.
    Recent patents on endocrine, metabolic & immune drug discovery, 2014, Volume: 8, Issue:1

    Topics: Antipsychotic Agents; Aripiprazole; Drug Partial Agonism; Drug Therapy, Combination; Humans; Hyperprolactinemia; Patents as Topic; Piperazines; Quinolones; Receptors, Dopamine D2

2014
A meta-analysis of efficacy and safety of aripiprazole in adult and pediatric bipolar disorder in randomized controlled trials and observational studies.
    Journal of affective disorders, 2016, Volume: 191

    Topics: Adolescent; Adult; Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Bipolar Disorder; Child; Gastrointestinal Diseases; Humans; Hyperprolactinemia; Male; Middle Aged; Observational Studies as Topic; Randomized Controlled Trials as Topic; Treatment Outcome; Weight Gain; Young Adult

2016
Multidisciplinary consensus on the therapeutic recommendations for iatrogenic hyperprolactinemia secondary to antipsychotics.
    Frontiers in neuroendocrinology, 2017, Volume: 45

    Topics: Antipsychotic Agents; Aripiprazole; Consensus; Humans; Hyperprolactinemia; Iatrogenic Disease; Mental Disorders

2017
Strategies for the treatment of antipsychotic-induced sexual dysfunction and/or hyperprolactinemia among patients of the schizophrenia spectrum: a review.
    Journal of sex & marital therapy, 2012, Volume: 38, Issue:3

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Drug Substitution; Drug Therapy, Combination; Erectile Dysfunction; Female; Humans; Hyperprolactinemia; Male; Piperazines; Psychotic Disorders; Purines; Quinolones; Schizophrenia; Schizophrenic Psychology; Sexual Dysfunction, Physiological; Sildenafil Citrate; Sulfones; Vasodilator Agents

2012
The promise of atypical antipsychotics: fewer side effects mean enhanced compliance and improved functioning.
    Postgraduate medicine, 2004, Volume: 116, Issue:4

    Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Diabetes Mellitus, Type 2; Dibenzothiazepines; Drug Administration Schedule; Humans; Hyperprolactinemia; Mental Disorders; Olanzapine; Patient Compliance; Piperazines; Practice Guidelines as Topic; Prescription Fees; Quetiapine Fumarate; Quinolones; Risk Assessment; Risperidone; Thiazoles; Torsades de Pointes; Treatment Outcome; Weight Gain

2004
Treatment of bipolar disorder: the evolving role of atypical antipsychotics.
    The American journal of managed care, 2007, Volume: 13, Issue:7 Suppl

    Topics: Antipsychotic Agents; Aripiprazole; Arrhythmias, Cardiac; Benzodiazepines; Bipolar Disorder; Diabetes Mellitus, Type 2; Dibenzothiazepines; Drug Evaluation; Drug Interactions; Drug Therapy, Combination; Dyslipidemias; Humans; Hyperprolactinemia; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Thiazoles; Treatment Outcome; Weight Gain

2007

Trials

13 trial(s) available for aripiprazole and Hyperprolactinaemia

ArticleYear
Effect of the addition of aripiprazole on hyperprolactinemia associated with risperidone long-acting injection.
    Journal of clinical psychopharmacology, 2013, Volume: 33, Issue:4

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Biomarkers; Chemistry, Pharmaceutical; Drug Administration Schedule; Female; Humans; Hyperprolactinemia; Injections; Male; Middle Aged; Pilot Projects; Piperazines; Prolactin; Quinolones; Risperidone; Schizophrenia; Spain; Time Factors; Treatment Outcome

2013
Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin).
    BMC psychiatry, 2013, Aug-22, Volume: 13

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Clinical Protocols; Dopamine Agonists; Female; Humans; Hyperprolactinemia; Piperazines; Quinolones; Research Design; Schizophrenia

2013
Efficacy and safety of aripiprazole in Chinese Han schizophrenia subjects: a randomized, double-blind, active parallel-controlled, multicenter clinical trial.
    Schizophrenia research, 2014, Volume: 157, Issue:1-3

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Asian People; Blood Pressure; China; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Electrocardiography; Female; Heart Rate; Humans; Hyperprolactinemia; Male; Piperazines; Psychiatric Status Rating Scales; Quinolones; Risperidone; Schizophrenia; Treatment Outcome; Weight Gain

2014
Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: A randomized, double-blind, placebo-controlled, dose-response study.
    Psychoneuroendocrinology, 2015, Volume: 58

    Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hyperprolactinemia; Male; Middle Aged; Prolactin; Risperidone; Schizophrenia; Treatment Outcome; Young Adult

2015
Adjunctive Aripiprazole Treatment for Risperidone-Induced Hyperprolactinemia: An 8-Week Randomized, Open-Label, Comparative Clinical Trial.
    PloS one, 2015, Volume: 10, Issue:10

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antipsychotic Agents; Aripiprazole; Blood Glucose; Body Mass Index; Cholesterol; Drug Administration Schedule; Etoposide; Female; Humans; Hyperprolactinemia; Lipoproteins, HDL; Male; Mitoxantrone; Prednisone; Prolactin; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Treatment Outcome; Triglycerides; Vincristine

2015
Once-monthly paliperidone palmitate compared with conventional and atypical daily oral antipsychotic treatment in patients with schizophrenia.
    CNS spectrums, 2016, Volume: 21, Issue:6

    Topics: Administration, Oral; Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodiazepines; Delayed-Action Preparations; Female; Haloperidol; Humans; Hyperprolactinemia; Injections, Intramuscular; Male; Middle Aged; Olanzapine; Paliperidone Palmitate; Perphenazine; Proportional Hazards Models; Quetiapine Fumarate; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Failure; Treatment Outcome

2016
Effect of Adjunctive Aripiprazole on Sexual Dysfunction in Schizophrenia: A Preliminary Open-Label Study.
    Pharmacopsychiatry, 2017, Volume: 50, Issue:2

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Drug Therapy, Combination; Female; Humans; Hyperprolactinemia; Male; Prolactin; Schizophrenia; Sexual Dysfunction, Physiological

2017
Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole.
    Progress in neuro-psychopharmacology & biological psychiatry, 2008, Dec-12, Volume: 32, Issue:8

    Topics: Adolescent; Adult; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Cross-Over Studies; Drug Therapy, Combination; Female; Humans; Hyperprolactinemia; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Risperidone; Schizophrenia; Severity of Illness Index; Sulpiride; Young Adult

2008
Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study.
    Schizophrenia research, 2009, Volume: 107, Issue:2-3

    Topics: Administration, Oral; Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hyperprolactinemia; Male; Middle Aged; Olanzapine; Piperazines; Prolactin; Psychotic Disorders; Quinolones; Risperidone; Schizophrenia; Sex Factors; Substance Withdrawal Syndrome; Young Adult

2009
Effectiveness of switching from aripiprazole to ziprasidone in patients with schizophrenia.
    Clinical neuropharmacology, 2010, Volume: 33, Issue:3

    Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Blood Glucose; Body Size; Body Weight; Diagnostic and Statistical Manual of Mental Disorders; Female; Hip; Humans; Hyperprolactinemia; Liver Function Tests; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Thiazoles; Treatment Outcome; Waist Circumference; Wakefulness; Young Adult

2010
Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.
    The Journal of clinical psychiatry, 2002, Volume: 63, Issue:9

    Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Body Weight; Double-Blind Method; Drug Administration Schedule; Electroencephalography; Female; Haloperidol; Humans; Hyperprolactinemia; Long QT Syndrome; Male; Piperazines; Placebos; Prolactin; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Schizophrenia; Schizophrenic Psychology; Secondary Prevention; Treatment Outcome

2002
Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: a pilot study.
    Progress in neuro-psychopharmacology & biological psychiatry, 2006, Volume: 30, Issue:4

    Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Female; Humans; Hyperprolactinemia; Middle Aged; Pilot Projects; Piperazines; Prolactin; Quinolones; Schizophrenia; Time Factors

2006
Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial.
    The American journal of psychiatry, 2007, Volume: 164, Issue:9

    Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Brief Psychiatric Rating Scale; Dopamine Antagonists; Double-Blind Method; Drug Therapy, Combination; Female; Haloperidol; Humans; Hyperprolactinemia; Male; Middle Aged; Piperazines; Placebos; Quinolones; Receptors, Dopamine D2; Schizophrenia; Schizophrenic Psychology; Sex Factors; Treatment Outcome

2007

Other Studies

57 other study(ies) available for aripiprazole and Hyperprolactinaemia

ArticleYear
Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.
    Journal of medicinal chemistry, 2007, Oct-18, Volume: 50, Issue:21

    Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzoxazines; Biogenic Monoamines; Humans; Hyperprolactinemia; Indoles; Metabolic Diseases; Phthalimides; Piperazines; Principal Component Analysis; Pyridines; Radioligand Assay; Receptors, Biogenic Amine; Weight Gain

2007
Discovery of a new class of multi-target heterocycle piperidine derivatives as potential antipsychotics with pro-cognitive effect.
    Bioorganic & medicinal chemistry letters, 2021, 05-15, Volume: 40

    Topics: Animals; Antipsychotic Agents; Behavior, Animal; Cognition; Dopamine; Drug Design; Humans; Hyperprolactinemia; Mice; Models, Animal; Movement; Piperidines; Protein Binding; Receptors, Histamine H3; Risperidone; Serotonin; Structure-Activity Relationship; Weight Gain

2021
Amisulpride withdrawal akathisia responding to aripiprazole with propranolol in first-onset psychosis: a case report.
    BMC psychiatry, 2022, 01-29, Volume: 22, Issue:1

    Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Benztropine; Female; Humans; Hyperprolactinemia; Prolactin; Propranolol; Psychomotor Agitation; Psychotic Disorders; Young Adult

2022
Relapse in patients with schizophrenia and amisulpride-induced hyperprolactinemia or olanzapine-induced metabolic disturbance after switching to other antipsychotics.
    Psychiatry research, 2023, Volume: 322

    Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chronic Disease; Humans; Hyperprolactinemia; Olanzapine; Piperazines; Quinolones; Recurrence; Schizophrenia

2023
Antipsychotic-Related Prolactin Levels and Sexual Dysfunction in Mentally Ill Youth: A 3-Month Cohort Study.
    Journal of the American Academy of Child and Adolescent Psychiatry, 2023, Volume: 62, Issue:9

    Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cohort Studies; Erectile Dysfunction; Female; Galactorrhea; Humans; Hyperprolactinemia; Male; Mentally Ill Persons; Olanzapine; Pregnancy; Prolactin; Prospective Studies; Quetiapine Fumarate; Risperidone

2023
Editorial: A Better Perspective on Antipsychotic-Related Hyperprolactinemia in Children and Adolescents.
    Journal of the American Academy of Child and Adolescent Psychiatry, 2023, Volume: 62, Issue:9

    Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Child; Dopamine; Female; Humans; Hyperprolactinemia; Male; Prolactin; Risperidone

2023
Therapeutic outcomes wide association scan of different antipsychotics in patients with schizophrenia: Randomized clinical trials and multi-ancestry validation.
    Psychiatry and clinical neurosciences, 2023, Volume: 77, Issue:9

    Topics: Antipsychotic Agents; Aripiprazole; Humans; Hyperprolactinemia; Lipids; Olanzapine; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Treatment Outcome

2023
Aripiprazole for the Management of Antipsychotic-Induced Hyperprolactinemia A Retrospective Case Series.
    The primary care companion for CNS disorders, 2020, Jan-30, Volume: 22, Issue:1

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Hyperprolactinemia; Middle Aged; Prolactin; Psychotic Disorders; Retrospective Studies; Schizophrenia

2020
The pharmacogenetics of aripiprazole-induced hyperprolactinemia: what do we know?
    Pharmacogenomics, 2020, Volume: 21, Issue:9

    Topics: Antipsychotic Agents; Aripiprazole; Humans; Hyperprolactinemia; Pharmacogenetics; Receptors, Dopamine; Receptors, Serotonin

2020
Guidance on the treatment of antipsychotic-induced hyperprolactinemia when switching the antipsychotic is not an option.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2021, 05-06, Volume: 78, Issue:10

    Topics: Antipsychotic Agents; Aripiprazole; Humans; Hyperprolactinemia; Mental Disorders; Prolactin

2021
Analysis of prolactin and sexual side effects in patients with schizophrenia who switched from paliperidone palmitate to aripiprazole lauroxil.
    Psychiatry research, 2021, Volume: 302

    Topics: Antipsychotic Agents; Aripiprazole; Female; Humans; Hyperprolactinemia; Male; Paliperidone Palmitate; Prolactin; Prospective Studies; Schizophrenia

2021
Hypoprolactinemia and hyperprolactinemia in male schizophrenia patients treated with aripiprazole and risperidone and their relationships with testosterone levels.
    Neuropsychopharmacology reports, 2021, Volume: 41, Issue:3

    Topics: Antipsychotic Agents; Aripiprazole; Female; Genetic Diseases, Inborn; Humans; Hyperprolactinemia; Lactation Disorders; Male; Paliperidone Palmitate; Prolactin; Risperidone; Schizophrenia; Testosterone

2021
Hyperprolactinemic Galactorrhea as a Side Effect of Aripiprazole: An Adolescent Case (Aripiprazole-Related Hyperprolactinemic Galactorrhea).
    Journal of clinical psychopharmacology, 2018, Volume: 38, Issue:2

    Topics: Adolescent; Adolescent Behavior; Antipsychotic Agents; Aripiprazole; Female; Galactorrhea; Humans; Hyperprolactinemia; Mood Disorders

2018
Treatment of Risperidone-Associated Hyperprolactinemia With Aripiprazole.
    Journal of clinical psychopharmacology, 2018, Volume: 38, Issue:5

    Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Female; Humans; Hyperprolactinemia; Risperidone

2018
Can low-dose aripiprazole reverse some of the adverse effects from a long-acting injectable?
    Schizophrenia research, 2019, Volume: 204

    Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Female; Humans; Hyperprolactinemia; Injections; Psychotic Disorders

2019
Impact of the CYP2D6 phenotype on hyperprolactinemia development as an adverse event of treatment with atypical antipsychotic agents in pediatric patients.
    Irish journal of medical science, 2019, Volume: 188, Issue:4

    Topics: Adolescent; Alleles; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Child; Cytochrome P-450 CYP2D6; Female; Humans; Hyperprolactinemia; Male; Phenotype; Prospective Studies; Psychotic Disorders; Risperidone; Schizophrenia; Young Adult

2019
Aripiprazole for the treatment of duloxetine-induced hyperprolactinemia: A case report.
    Journal of affective disorders, 2019, 05-01, Volume: 250

    Topics: Adolescent; Amenorrhea; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Drug Therapy, Combination; Duloxetine Hydrochloride; Female; Galactorrhea; Humans; Hyperprolactinemia; Menstruation Disturbances; Prolactin; Receptors, Dopamine D2

2019
Prolactin deficiency by aripiprazole.
    Journal of clinical psychopharmacology, 2014, Volume: 34, Issue:4

    Topics: Antipsychotic Agents; Aripiprazole; Genetic Diseases, Inborn; Humans; Hyperprolactinemia; Lactation Disorders; Piperazines; Prolactin; Quinolones

2014
Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs.
    JAMA internal medicine, 2014, Volume: 174, Issue:12

    Topics: Adult; Aged; Aripiprazole; Benzothiazoles; Compulsive Behavior; Consumer Behavior; Dopamine Agonists; Drug Labeling; Female; Gambling; Humans; Hyperprolactinemia; Impulsive Behavior; Indoles; Male; Middle Aged; Parkinson Disease; Piperazines; Pramipexole; Quinolones; Receptors, Dopamine D3; Restless Legs Syndrome; Retrospective Studies; Sexual Behavior; United States; United States Food and Drug Administration

2014
Paliperidone and aripiprazole differentially affect the strength of calcium-secretion coupling in female pituitary lactotrophs.
    Scientific reports, 2015, Mar-10, Volume: 5

    Topics: Animals; Aripiprazole; Calcium Signaling; Dopamine; Female; Humans; Hyperprolactinemia; Lactotrophs; Paliperidone Palmitate; Prolactin; Rats; Schizophrenia; Signal Transduction

2015
Using aripiprazole to treat new-onset hyperprolactinemia-related delusion of pregnancy.
    The Australian and New Zealand journal of psychiatry, 2015, Volume: 49, Issue:10

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Delusions; Female; Humans; Hyperprolactinemia; Risperidone; Schizophrenia

2015
Aripiprazole long-acting injection: promising but more evidence needed.
    Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists, 2016, Volume: 24, Issue:4

    Topics: Antipsychotic Agents; Aripiprazole; Humans; Hyperprolactinemia; Injections, Intramuscular; Schizophrenia; Weight Gain

2016
Add-on effects of a low-dose aripiprazole in resolving hyperprolactinemia induced by risperidone or paliperidone.
    Psychiatry research, 2016, Mar-30, Volume: 237

    Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Drug Therapy, Combination; Estradiol; Female; Humans; Hyperprolactinemia; Middle Aged; Paliperidone Palmitate; Prolactin; Risperidone; Schizophrenia; Treatment Outcome; Young Adult

2016
[Plasma levels of antipsychotics and the severity of side-effects in the treatment of schizophrenia exacerbation].
    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2015, Volume: 115, Issue:11

    Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Clozapine; Depression; Drug Therapy, Combination; Female; Haloperidol; Humans; Hyperprolactinemia; Male; Middle Aged; Olanzapine; Prolactin; Risperidone; Schizophrenia; Schizophrenic Psychology; Young Adult

2015
Aripiprazole for the Treatment of Antipsychotic-Induced Hyperprolactinemia in an Adolescent Boy.
    Journal of child and adolescent psychopharmacology, 2016, Volume: 26, Issue:5

    Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Humans; Hyperprolactinemia; Male; Prolactin; Quinolones; Schizophrenia

2016
Aripiprazole-Associated Hypoprolactinemia in the Clinical Setting.
    Journal of clinical psychopharmacology, 2016, Volume: 36, Issue:4

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Hyperprolactinemia; Male; Middle Aged; Prolactin; Retrospective Studies

2016
Hyperprolactinemia, prolactin-related side effects and quality of life in Chinese psychiatric patients.
    Comprehensive psychiatry, 2016, Volume: 71

    Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Case-Control Studies; China; Clozapine; Female; Humans; Hyperprolactinemia; Male; Mental Disorders; Quality of Life; Risperidone; Sexual Dysfunction, Physiological; Young Adult

2016
Partial regimen replacement with aripiprazole reduces serum prolactin in patients with a long history of schizophrenia: A case series.
    Asian journal of psychiatry, 2017, Volume: 25

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Hyperprolactinemia; Japan; Male; Middle Aged; Prolactin; Schizophrenia; Treatment Outcome

2017
Aripiprazole resolves amisulpride and ziprasidone-induced hyperprolactinemia.
    Psychiatry and clinical neurosciences, 2008, Volume: 62, Issue:5

    Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Female; Humans; Hyperprolactinemia; Long-Term Care; Piperazines; Quinolones; Schizophrenia, Paranoid; Sulpiride; Thiazoles; Young Adult

2008
Aripiprazole treatment of risperidone-induced hyperprolactinemia.
    The Journal of clinical psychiatry, 2009, Volume: 70, Issue:7

    Topics: Antipsychotic Agents; Aripiprazole; Humans; Hyperprolactinemia; Piperazines; Prospective Studies; Quinolones; Risperidone; Schizophrenia

2009
Attenuation of risperidone-induced hyperprolactinemia with the addition of aripiprazole.
    Journal of clinical pharmacy and therapeutics, 2009, Volume: 34, Issue:5

    Topics: Aripiprazole; Humans; Hyperprolactinemia; Male; Middle Aged; Piperazines; Quinolones; Receptors, Dopamine D2; Risperidone

2009
Treatment with aripiprazole for hyperprolactinemia induced by pituitary microadenoma in a bipolar I disorder patient.
    Journal of clinical psychopharmacology, 2010, Volume: 30, Issue:1

    Topics: Adenoma; Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Dopamine Antagonists; Female; Humans; Hyperprolactinemia; Piperazines; Pituitary Neoplasms; Quinolones

2010
Benefits of switching women schizophrenic patients to aripiprazole: a case study and brief review of the literature.
    Archives of women's mental health, 2010, Volume: 13, Issue:5

    Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Diagnostic and Statistical Manual of Mental Disorders; Dopamine Antagonists; Drug Substitution; Drug Therapy, Combination; Female; Humans; Hyperprolactinemia; Middle Aged; Piperazines; Prolactin; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Secondary Prevention

2010
Potential control of antipsychotic-induced hyperprolactinemia and obesity in children and adolescents by aripiprazole.
    Progress in neuro-psychopharmacology & biological psychiatry, 2010, Aug-16, Volume: 34, Issue:6

    Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Child; Humans; Hyperprolactinemia; Obesity; Piperazines; Quinolones; Schizophrenia

2010
Hyperprolactinaemia during treatment with paliperidone.
    Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists, 2010, Volume: 18, Issue:3

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Dibenzothiazepines; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Monitoring; Female; Galactorrhea; Humans; Hyperprolactinemia; Isoxazoles; Middle Aged; Paliperidone Palmitate; Patient Compliance; Piperazines; Prolactin; Psychotic Disorders; Pyrimidines; Quetiapine Fumarate; Quinolones; Recurrence; Schizophrenia, Paranoid; Young Adult

2010
Using aripiprazole to attenuate paliperidone-induced hyperprolactinemia.
    Progress in neuro-psychopharmacology & biological psychiatry, 2010, Aug-16, Volume: 34, Issue:6

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Drug Therapy, Combination; Female; Humans; Hyperprolactinemia; Isoxazoles; Paliperidone Palmitate; Piperazines; Pyrimidines; Quinolones; Schizophrenia, Paranoid; Treatment Outcome

2010
Adjunctive treatment with low-dosage aripiprazole for blonanserin-induced hyperprolactinemia in a female patient with schizophrenia.
    Progress in neuro-psychopharmacology & biological psychiatry, 2010, Oct-01, Volume: 34, Issue:7

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Dopamine Antagonists; Female; Humans; Hyperprolactinemia; Piperazines; Piperidines; Quinolones; Schizophrenia

2010
Differential add-on effects of aripiprazole in resolving hyperprolactinemia induced by risperidone in comparison to benzamide antipsychotics.
    Progress in neuro-psychopharmacology & biological psychiatry, 2010, Dec-01, Volume: 34, Issue:8

    Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzamides; Drug Synergism; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hyperprolactinemia; Male; Middle Aged; Piperazines; Prolactin; Prospective Studies; Quinolones; Risperidone; Young Adult

2010
Dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia.
    Journal of clinical psychopharmacology, 2010, Volume: 30, Issue:5

    Topics: Adult; Aripiprazole; Dose-Response Relationship, Drug; Female; Humans; Hyperprolactinemia; Middle Aged; Piperazines; Prolactin; Quinolones; Risperidone; Schizophrenia; Treatment Outcome

2010
Management of a patient with schizophrenia and underlying pituitary macroadenoma.
    Annals of the Academy of Medicine, Singapore, 2010, Volume: 39, Issue:11

    Topics: Adenoma; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bromocriptine; Dopamine Antagonists; Female; Hormone Antagonists; Humans; Hyperprolactinemia; Olanzapine; Piperazines; Pituitary Neoplasms; Quinolones; Risperidone; Schizophrenia; Serotonin Antagonists; Trifluoperazine

2010
Preliminary report: a naturalistic study of the effect of aripiprazole addition on risperidone-related hyperprolactinemia in patients treated with risperidone long-acting injection.
    Journal of clinical psychopharmacology, 2011, Volume: 31, Issue:1

    Topics: Adult; Aripiprazole; Delayed-Action Preparations; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hyperprolactinemia; Injections; Male; Middle Aged; Piperazines; Quinolones; Risperidone; Schizophrenia

2011
Comment on "dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia".
    Journal of clinical psychopharmacology, 2011, Volume: 31, Issue:3

    Topics: Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Hyperprolactinemia; Piperazines; Quinolones; Risperidone; Schizophrenia

2011
Effects of the dopamine stabilizers (S)-(-)-OSU6162 and ACR16 on prolactin secretion in drug-naive and monoamine-depleted rats.
    Naunyn-Schmiedeberg's archives of pharmacology, 2011, Volume: 384, Issue:1

    Topics: Animals; Aripiprazole; Dopamine; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Haloperidol; Hyperprolactinemia; Lactotrophs; Male; Methyltyrosines; Piperazines; Piperidines; Prolactin; Quinolones; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Reserpine

2011
Granulomatous cutaneous lesions associated with risperidone-induced hyperprolactinemia in an amputated upper limb.
    International journal of dermatology, 2012, Volume: 51, Issue:1

    Topics: Amputation Stumps; Antipsychotic Agents; Aripiprazole; Forearm; Granuloma; Humans; Hyperprolactinemia; Male; Middle Aged; Piperazines; Quinolones; Risperidone; Schizophrenia; Skin Diseases; Treatment Outcome

2012
Hypogonadism due to hyperprolactinemia and subsequent first episode of psychosis.
    Gender medicine, 2012, Volume: 9, Issue:1

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Cabergoline; Ergolines; Humans; Hyperprolactinemia; Hypogonadism; Male; Obesity, Morbid; Piperazines; Pituitary Neoplasms; Prolactin; Prolactinoma; Psychotic Disorders; Quinolones; Schizophrenia

2012
Hyperprolactinaemia on depot risperidone treated with aripiprazole.
    The Australian and New Zealand journal of psychiatry, 2012, Volume: 46, Issue:8

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Drug Monitoring; Drug Substitution; Female; Humans; Hyperprolactinemia; Medication Therapy Management; Pharmacovigilance; Piperazines; Quinolones; Risperidone; Schizophrenia; Treatment Outcome

2012
Successful switch to aripiprazole after induction of hyperprolactinemia by ziprasidone: a case report.
    The Journal of clinical psychiatry, 2004, Volume: 65, Issue:9

    Topics: Adult; Ambulatory Care; Antipsychotic Agents; Aripiprazole; Female; Humans; Hyperprolactinemia; Piperazines; Prolactin; Quinolones; Schizophrenia, Paranoid; Sexual Dysfunctions, Psychological; Thiazoles

2004
Reversal of symptomatic hyperprolactinemia by aripiprazole.
    The American journal of psychiatry, 2005, Volume: 162, Issue:8

    Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Dopamine Agonists; Drug Therapy, Combination; Female; Humans; Hyperprolactinemia; Injections, Intramuscular; Piperazines; Quinolones; Risperidone; Schizophrenia; Treatment Outcome

2005
Atypical antipsychotics and pituitary tumors: a pharmacovigilance study.
    Pharmacotherapy, 2006, Volume: 26, Issue:6

    Topics: Adolescent; Adverse Drug Reaction Reporting Systems; Amenorrhea; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Child; Clozapine; Dibenzothiazepines; Female; Galactorrhea; Gynecomastia; Haloperidol; Humans; Hyperprolactinemia; Male; Olanzapine; Piperazines; Pituitary Neoplasms; Quetiapine Fumarate; Quinolones; Retrospective Studies; Risperidone; Sex Factors; Thiazoles; United States; United States Food and Drug Administration

2006
Amisulpride-induced hyperprolactinaemia is not reversed by addition of aripiprazole.
    The international journal of neuropsychopharmacology, 2007, Volume: 10, Issue:1

    Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Dopamine Agonists; Dopamine Antagonists; Drug Therapy, Combination; Female; Humans; Hyperprolactinemia; Middle Aged; Piperazines; Quinolones; Schizophrenia; Sulpiride; Treatment Failure

2007
Reversal of antipsychotic-induced hyperprolactinemia, weight gain, and dyslipidemia by aripiprazole: A case report.
    The Journal of clinical psychiatry, 2006, Volume: 67, Issue:8

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Dyslipidemias; Female; Humans; Hyperprolactinemia; Obesity; Piperazines; Quinolones; Risperidone; Schizophrenia, Paranoid; Treatment Outcome; Weight Gain

2006
Hyperprolactinemia and amenorrhea associated with olanzapine normalized after addition of aripiprazole.
    Journal of clinical pharmacy and therapeutics, 2007, Volume: 32, Issue:2

    Topics: Adult; Amenorrhea; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Drug Interactions; Drug Therapy, Combination; Female; Humans; Hyperprolactinemia; Olanzapine; Piperazines; Quinolones

2007
Aripiprazole: what is the role of dopamine D(2) receptor partial agonism?
    The American journal of psychiatry, 2007, Volume: 164, Issue:9

    Topics: Antipsychotic Agents; Aripiprazole; Drug Therapy, Combination; Haloperidol; Humans; Hyperprolactinemia; Piperazines; Quinolones; Receptors, Dopamine D2; Schizophrenia; Serotonin 5-HT2 Receptor Antagonists; Synaptic Transmission

2007
Resolution of haloperidol-induced hyperprolactinemia with aripiprazole.
    Journal of clinical psychopharmacology, 2007, Volume: 27, Issue:5

    Topics: Adult; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Clonazepam; Dose-Response Relationship, Drug; Drug Therapy, Combination; Gynecomastia; Haloperidol; Humans; Hyperprolactinemia; Male; Piperazines; Prolactin; Quinolones; Valproic Acid

2007
Aripiprazole resolves symptomatic hyperprolactinemia in a male schizophrenic patient.
    Progress in neuro-psychopharmacology & biological psychiatry, 2008, Apr-01, Volume: 32, Issue:3

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Humans; Hyperprolactinemia; Male; Piperazines; Quinolones; Schizophrenia; Sulpiride

2008
Change in sexual dysfunction with aripiprazole: a switching or add-on study.
    Journal of psychopharmacology (Oxford, England), 2008, Volume: 22, Issue:3

    Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Ejaculation; Erectile Dysfunction; Female; Humans; Hyperprolactinemia; Libido; Male; Menstruation Disturbances; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Sex Characteristics; Sexual Dysfunction, Physiological; Surveys and Questionnaires

2008
Adjunctive versus monotherapeutic treatment for schizophrenia: addressing antipsychotic side effects.
    The American journal of psychiatry, 2008, Volume: 165, Issue:3

    Topics: Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Dose-Response Relationship, Drug; Drug Costs; Drug Therapy, Combination; Haloperidol; Humans; Hyperprolactinemia; Piperazines; Polypharmacy; Quinolones; Schizophrenia

2008